Union Minister Dr. Jitendra Singh launched Sujvika, India’s first sovereign AI-powered biotech data portal, designed to aggregate, analyze, and democratize access to biological and genomic datasets. The platform aims to accelerate R&D in vaccines, therapeutics, precision medicine, and bio-manufacturing by providing researchers, startups, and industry with secure, searchable, and AI-enriched insights while ensuring complete data sovereignty and compliance with national privacy standards.
Glimpse:
Sujvika integrates fragmented biotech datasets from academic labs, government institutes, public health programs, and private sector sources into a unified, AI-searchable repository. It supports advanced queries, pattern recognition, predictive modelling, and visualization tools to help identify novel drug targets, repurpose existing molecules, and support clinical trial design. The portal is fully hosted in India, complies with DPDP Act and ABDM guidelines, and is now open to registered researchers, biotech startups, and academic institutions with tiered access levels to balance openness and security.
Union Minister of State (Independent Charge) for Science & Technology, Dr. Jitendra Singh, formally inaugurated Sujvika India’s first national AI-driven biotech data portal at a high-profile event in New Delhi on February 26, 2026. Developed under the joint leadership of the Department of Biotechnology (DBT), Biotechnology Industry Research Assistance Council (BIRAC), and the IndiaAI Mission, Sujvika represents a major milestone in India’s ambition to build a self-reliant, data-rich bioeconomy capable of competing globally in vaccines, biologics, precision medicine, and synthetic biology.
Sujvika aggregates de-identified biological, genomic, proteomic, and clinical datasets from diverse sources including ICMR, CSIR labs, DBT-funded projects, public hospitals, and willing private sector partners. The platform employs advanced AI models to enable natural language search, automated pattern discovery, cross-dataset correlation, predictive target identification, and visualization of complex biological relationships. Researchers can query in plain English or scientific terms, receive ranked results with confidence scores, and explore interactive dashboards showing disease-gene-drug associations, pathway maps, and variant frequencies specific to Indian populations.
Dr. Jitendra Singh, while launching the portal, emphasized that Sujvika addresses a long-standing gap: India generates enormous biological data through its large patient volumes and public health programs but has lacked a centralized, AI-enabled repository to convert raw data into actionable insights. He highlighted that the platform will empower startups, academic researchers, and biotech companies to accelerate discovery of new therapies for diseases disproportionately affecting India such as tuberculosis, diabetes complications, tropical infections, and rare genetic disorders while reducing dependence on foreign databases.
The portal operates under strict data sovereignty principles: all storage and processing occur within India on secure government-approved cloud infrastructure, with granular consent management, anonymization protocols, and role-based access controls compliant with the Digital Personal Data Protection Act (DPDP) and ABDM standards. Registered users from academic institutions, startups, and industry receive tiered access from basic search to advanced analytics and collaborative workspaces while maintaining full traceability and auditability.
The launch was accompanied by the onboarding of initial datasets from major national programs and research consortia, with commitments from several ICMR centres, CSIR labs, and private biotech firms to contribute additional data in the coming months. Dr. Rajesh Gokhale, Secretary of DBT, announced that Sujvika will be linked with national supercomputing facilities to support large-scale AI training and simulation, enabling faster hypothesis generation and virtual screening of drug candidates.
The initiative is expected to catalyze hundreds of new research projects, strengthen India’s biotech startup ecosystem, and position the country as a major contributor to global life sciences knowledge while safeguarding national data interests.
“Sujvika is more than a data portal it is India’s sovereign engine for biotech innovation. By unlocking our own biological data with AI, we are writing the next chapter of self-reliant discovery for the benefit of humanity.”
By
HB Team
